Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Oncofertility w praktyce klin.
  • Obniżka

Calcium Antagonists in Clinical Medicine

9781560534969
459,00 zł
413,00 zł Zniżka 46,00 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 413,00 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
This thoroughly revised and expanded new edition presents the current state of knowledge of the diverse applications of calcium antagonists and makes recommendations about their appropriate use. New sections have been added on Clinical Pharmacology and Metabolic Effects. Sixteen new chapters have been added on such topics as Pharmacogenetics of Hypertension:: Using Gene Markers to Infer Pathogenesis and Guide Therapy, New Pharmacologic Directions for Calcium Channel Blockers, Calcium Channel Blocker Use in End-Stage Renal Disease:: Pharmacokinetics and Pharmacodynamics, and many others.
Szczegóły produktu
Hanley & Belfus
30910
9781560534969
9781560534969

Opis

Rok wydania
2002
Numer wydania
3
Oprawa
twarda
Liczba stron
852
Waga (g)
1374
  • BASIC PRINCIPLES
    1. Mechanisms of Action of Calcium Antagonists (David J. Triggle, PhD)
    2. Alterations in Cardiovascular Cation Metabolism in the Cardiometabolic Syndrome (Dmitri Kirpichnikov, Samy McFarlane, Nate Winer, and James Sowers)
    3. Endothelial Regulation of Vascular Tone and Growth:: Role of Calcium Antagonists (Thomas F. Lüscher, MD, and Rene R. Wenzel, MD, and Georg Nool, MD)
    4. Endothelial Dysfunction:: Evolving Perspectives for Pathogenesis & Calcium Antagonist Therapy (Massimo Volpe)

    CLINICAL PHARMACOLOGY
    5. Pharmacokinetics of Calcium Antagonists:: Implications for Therapy (Henry L. Elliott, MD, FRCP, and Peter A. Meredith, PhD)
    6. Calcium Antagonists and the Cytochrome P450 System (Domenic Sica)
    7. Time-Effect Profile and Duration of Action of Calcium Antagonists:: Implications for Rational Management (Faiez Zannad)
    8. Ambulatory Blood Pressure Monitoring in the Evaluation ofAntihypertensive Treatment with Calcium Antagonists (Giuseppe Mancia)
    9. Controlled-Release Formulations of the Calcium Antagonists (William J. Elliott, MD, PhD)
    10. Novel Therapeutic Applications for Calcium Antagonists:: Atherosclerotic Plaque Stabilization (R. Preston Mason)

    METABOLIC EFFECTS
    11. Insulin and Glucoregulatory Hormones:: Implications for Antihypertensive Therapy (Dalila B. Corry, MD, and Michael L. Tuck, MD)
    12. Effects of Calcium Antagonists on Lipids (Ronald B. Goldberg, MD, and Hermes Florez, MD, MPH)

    THE HEART
    13. Effect of Calcium Antagonists on Hemodynamics, Left Ventricular Mass and Myocardial Flow Reserve (Robert A. Phillips, MD, PhD and Joseph Diamond, MD)
    14. Cardiac Effects of Calcium Antagonists in Hypertension (Ehud Grossman, MD, and Franz H. Messerli, MD)
    15. Calcium Antagonists and Myocardial Ischemia (George W. Vetrovec, MD)
    16. The Therapeutic Potential of Calcium Antagonists for Lethal Ventricular Arrhythmias:: Ischemia-selective Antagonists May Prevent Ventricular Fibrillation (George E. Billman, PhD)
    17. The Clinical Antiarrhythmic Effectiveness of Calcium Antagonists (Simon Chakko, MD)
    18. Are Calcium Antagonists Proarrhythmic? (Simon Chakko, MD, and Murray Epstein, MD, FACP)

    HYPERTENSION
    19. Calcium Antagonists in the Management of Hypertension (Murray Epstein, MD, FACP)
    20. Hemodynamic Effects of Calcium Antagonists in Hypertension (Per Lund-Johansen, MD)
    21. Systolic Blood Pressure and Pulse Pressure as Determinants of Cardiovascular Risk:: Implications for Rational Therapy (William White)
    22. Arterial Compliance and Effect of Calcium Antagonists (Gerard M. London, MD, and Michel E. Safar, MD)
    23. The Role of Calcium Antagonists in Cardiovascular Prevention:: A Meta-analysis of Recent Trials (Ji-Guang Wang, and Jan Staessen)

    SPECIAL POPULATIONS
    24. Diabetic Nephropathy:: Focus on the Renin-Angiotensin System and Calcium Channel Blockade (Murray Epstein, MD, FACP, and Mark E. Cooper, MD, FRACP)
    25. Calcium Antagonists:: Are They All Created Equal in Regard to Slowing Progression of Diabetic Nephropathy? (George L. Bakris, MD, FACP, and Munavvar Izhar, MD)
    26. Calcium Antagonists as Antihypertensive Agents in African-American Patients (John M. Flack, MD, MPH)
    27. Drug Responsiveness and Side Effects:: Lessons from Chinese Populations (Juliana Chan, MD, Wilson Y.S. Leung, Bpharm, and Julian A.J.H. Critchley, PhD)
    28. Pharmacogenetic Markers of Hypertension:: Pathogenesis and Responses to Therapy (Stephen T. Turner, MD)
    29. Calcium Antagonists in Elderly Patients with Systemic Hypertension (William H. Frishman, MD, and Atif Qureshi, MD)
    30. Management of High Blood Pressure in Pregnancy (Marshall D. Lindheimer, MD, and Dr. Edgardo Abalos)


    CALCIUM ANTAGONISTS IN THE TREATMENT OF NONCARDIOVASCULAR DISORDERS
    31. Calcium Antagonists and Central Nervous System Diseases (Alexander Scriabine, MD)

    CALCIUM ANTAGONISTS AND THE KIDNEY
    32. Renal Hemodynamic Effects of Calcium Antagonists (Koichi Hayashi, MD, PhD, Takao Saruta, MD, PhD, and Murray Epstein, MD, FACP)
    33. Effects of Calcium Antagonists on Vasoactive Hormones (Jesús Egido, MD, PhD, Jose Tuńon, MD, Nieves Tarin, MD)
    34. The Clinical Utility of Calcium Antagonists in Renal Transplant Recipients (Matthew R. Weir, MD)
    35. Calcium Antagonists and the Kidney; Implications for Renal Protection (Murray Epstein, MD, FACP)
    36. Ambulatory Blood Pressure:: Implications for Renal Dysfunction (Josep Redon)
    37. Salt Sensitivity and Microalbumuria:: Implications for Pathogenesis and Management (Vito Campese)
    38. Calcium Antagonists and End-Stage Renal Disease:: Pharmacokinetics and Pharmacodynamics (Domenic Sica)

    EMERGING PERSPECTIVES
    39. Fixed-dose Combination Therapy with Calcium Antagonists (Murray Epstein, MD, FACP, and Bernard Waeber, MD)
    40. Inproving the Cost-effectiveness of Treating Hypertension (William J. Elliott, MD, PhD)
    41. Effects of Calcium Antagonists on Atherosclerosis (José Tuńón, Nieves Tarín, and Jesús Egido)
    42. Sympathoinhibitory and Sympathoexcitatory Effects of Dihydropyridine Calcium Antagonists (Frans H. H. Leenen, MD, PhD, FRCPC)
    43. Apoptosis and Risk with the Use of Calcium Antagonists(Nanette Bishopric)
    44. Safety of Calcium Antagonists as Antihypertensive Agents:: An Update (Murray Epstein, MD, FACP)
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów